A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults - MI-CP215

Study identifier:MI-CP215

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of MEDI3414 in Adults

Medical condition

Healthy

Phase

Phase 4

Healthy volunteers

Yes

Study drug

Sex

All

Actual Enrollment

300

Study type

Interventional

Age

18 Years - 49 Years

Date

Study Start Date: 01 Aug 2009

Primary Completion Date: 01 Sept 2009

Study Completion Date: 01 Mar 2010

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Prevention

Verification:

Verified 01 Sept 2011 by MedImmune, LLC

Collaborators

Department of Health and Human Services

Inclusion and exclusion criteria

Inclusion Criteria

- Male or female, 18 to 49 years of age (not yet reached their 50th birthday) at the time of randomization
- Healthy by medical history and physical examination
- Written informed consent and any locally required authorization (eg, Health Insurance Portability and Accountability Act [HIPAA] in the United States of America [USA], European Union [EU] Data Privacy Directive in the EU) obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations
- Females of childbearing potential, (ie, unless surgically sterile [eg, bilateral tubal ligation, bilateral oophorectomy, or hysterectomy], has sterile male partner, is at least 1 year post menopause, or practices abstinence) must use an effective method of avoiding pregnancy (including oral, transdermal, or implanted contraceptives, intrauterine device, female condom with spermicide, diaphragm with spermicide, cervical cap, or use of a condom with spermicide by the sexual partner) for 30 days prior to the first dose of investigational product, and must agree to continue using such precautions for 60 days after the second dose of investigational product. In addition, the subject must also have a negative urine or blood pregnancy test at screening and, if screening and Day 1 do not occur on the same day, on the day of vaccination prior to randomization.
- Males, unless not sexually active, must use an effective method of birth control with a female partner and must agree to continue using such contraceptive precautions for at least 30 days after the second dose of investigational product (from Day 1 through Day 59 of the study)
- Subject is available by telephone
- Subject is able to understand and comply with the requirements of the protocol, as judged by the investigator
- Subject is able to complete follow-up period of 180 days after Dose 2 as required by the protocol

Exclusion Criteria

- History of hypersensitivity to any component of the investigational product including egg or egg protein, gelatin or arginine, or serious, life-threatening, or severe reactions to previous influenza vaccinations
- History of hypersensitivity to gentamicin
- Any condition for which the inactivated influenza vaccine is indicated, including chronic disorders of the pulmonary or cardiovascular systems (eg, asthma), chronic metabolic diseases (eg, diabetes mellitus), renal dysfunction, or hemoglobinopathies that required regular medical follow-up or hospitalization during the preceding year
- Acute febrile (> 100.0°F oral or equivalent) and/or clinically significant respiratory illness (eg, cough or sore throat) within 14 days prior to randomization
- History of asthma
- Any known immunosuppressive condition or immune deficiency disease, including human immunodeficiency virus infection, or ongoing immunosuppressive therapy
- History of Guillain-Barré syndrome
- A household contact who is severely immunocompromised (eg, hematopoietic stem cell transplant recipient, during those periods in which the immunocompromised individual requires care in a protective environment); subject should additionally avoid close contact with severely immunocompromised individuals for at least 21 days after receipt of investigational product
- Receipt of any investigational agent within 30 days prior to randomization, or expected receipt through 30 days after the second dose of investigational product (use of licensed agents for indications not listed in the package insert is permitted)
- Expected receipt of antipyretic or analgesic medication on a daily or every other day basis from randomization through 14 days after receipt of each dose of investigational product
- Administration of intranasal medications within 14 days prior to randomization, or expected receipt through 14 days after administration of each dose of investigational product
- Receipt of any nonstudy vaccine within 30 days before or after Dose 1 or expected receipt of any nonstudy vaccine within 30 days before or after Dose 2
- Known or suspected mitochondrial encephalomyopathy
- Subject is pregnant or a nursing mother
- Any condition (eg, chronic cough, allergic rhinitis) that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results
- Subject or immediate family member of subject is an employee of the clinical study site or is otherwise in involved with the conduct of the study

Location

Covance Daytona Beach

Daytona Beach, FL, United States, 30060

Location

Pharmax Research Clinic

Miami, FL, United States, 33126

Location

Miami Research Associates

South Miami, FL, United States, 33143

Location

Center for Pharmaceutical Research

Kansas City, MO, United States, 64114

Location

Clinical Research Associates, Inc.

Nashville, TN, United States, 37203

Arms	Assigned Interventions
Experimental: MEDI3414 [Influenza A (H1N1) vaccine] MEDI3414 - Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10^7 fluorescent focus units (FFU) of live, attenuated influenza virus reassortant A/California/7/2009 strain that was propagated in chicken eggs. H1N1 monovalent influenza vaccine (MEDI3414) contained no preservatives and no adjuvants.	Biological/Vaccine: MEDI3414 [Influenza A/H1N1 live attenuated, intranasal] 0.5 mL; (intranasal sprayer) Other Name: MEDI3414
Placebo Comparator: Placebo Placebo -Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.	Other: Placebo (intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer)

Arms

Assigned Interventions

Experimental: MEDI3414 [Influenza A (H1N1) vaccine]
MEDI3414 - Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10^7 fluorescent focus units (FFU) of live, attenuated influenza virus reassortant A/California/7/2009 strain that was propagated in chicken eggs. H1N1 monovalent influenza vaccine (MEDI3414) contained no preservatives and no adjuvants.

Biological/Vaccine: MEDI3414 [Influenza A/H1N1 live attenuated, intranasal]
0.5 mL; (intranasal sprayer)

Other Name: MEDI3414

Placebo Comparator: Placebo
Placebo -Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.

Other: Placebo
(intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer)

Documents available

Click here and search for drug information provided by the FDA.
Download
Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
Download
Click here to find results for studies related to marketed products.
Download
Trial Results Summaries
Available here